Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amrinone (also known as inamrinone) is a bipyridine derivative that functions as a selective phosphodiesterase 3 (PDE3) inhibitor. It exerts both positive inotropic and vasodilatory effects by increasing intracellular cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle. Clinically, it is primarily indicated for the short-term management of severe congestive heart failure. Amrinone has been extensively investigated for its ability to reduce pulmonary vascular resistance and improve right ventricular function in patients with pulmonary hypertension, particularly in the context of cardiac surgery, heart transplantation, and mitral stenosis. Due to potential confusion with amiodarone, the official name was changed to inamrinone in many jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amrinone.